Oncopharmpod
Cross-Trial Comparison Don'ts
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:19:31
- More information
Informações:
Synopsis
We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.
